+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Multi-Gyn FemiTotal vaginal gel for treating and preventing bacterial vaginosis BV and vulvovaginal candidiasis VVC symptoms in women. This trial includes 40 women with itching symptoms of VVC and 49 women with BV diagnosed using Amsel criteria. The main goal is to assess relief of itching and treatment effectiveness 21 days after starting the gel. Participants will use the Multi-Gyn FemiTotal vaginal gel for 7 days during the treatment phase. If symptoms are considered cured 21 days after starting treatment, they will enter a prevention phase where they are followed up for 4 months to monitor any recurrence of BV or VVC. The study is a single group, prospective clinical investigation led by Karo Pharma AB. During the study, participants will be evaluated by investigators using clinical assessments and questionnaires to measure treatment effectiveness at 21 days. Follow-up visits will continue until 4 months after treatment initiation to check for re-occurrence of infections. The study tracks symptom relief, treatment safety, and prevention of BV and VVC return over this period.

Age: 18Years +FEMALEPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the medical device cream RV4421B-EV0407 for the treatment of various types of eczema, including atopic eczema, contact eczema, and chronic hand eczema. This study involves a diverse group of adults and children, including those with darker skin tones, to assess the safety and efficacy of the cream used alone or alongside topical corticosteroids over a period of 12 weeks with an additional follow-up. Participants will apply the product twice daily, either by itself or with topical corticosteroid therapy, depending on their age group. The study includes three groups infants 3 months to 23 months, children 24 months to 12 years, and teenagers and adults 13 years and older. The product application period lasts up to 87 days. During the study, participants will attend five visits an inclusion visit on day 1, two intermediate visits including one by phone between days 8 and 15 and one on day 29, another visit on day 57, and a final visit on day 85. Researchers will monitor local tolerance to the product, adverse events, and atopic dermatitis severity using various assessments. Quality of life questionnaires and satisfaction surveys will also be completed, with continuous monitoring throughout the study period.

Age: 3Months +All GendersPhase Not Applicable
1 location